Reviewing Akari Therapeutics (NASDAQ:AKTX) & Innate Pharma (NASDAQ:IPHA)

Akari Therapeutics (NASDAQ:AKTX) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by insiders. Comparatively, 31.9% of Innate Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Akari Therapeutics and Innate Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1	0	3	0	2.50
Innate Pharma	1	0	5	0	2.67

Akari Therapeutics currently has a consensus price target of $32.33, suggesting a potential upside of 202.18%. Innate Pharma has a consensus price target of $6.67, suggesting a potential upside of 200.30%. Given Akari Therapeutics’ higher possible upside, equities analysts plainly believe Akari Therapeutics is more favorable than Innate Pharma.

Profitability

This table compares Akari Therapeutics and Innate Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-147.45%	-74.70%
Innate Pharma	N/A	N/A	N/A

Valuation & Earnings

This table compares Akari Therapeutics and Innate Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30 million	N/A	N/A
Innate Pharma	$10.19 million	20.49	-$55.64 million	N/A	N/A

Akari Therapeutics has higher earnings, but lower revenue than Innate Pharma.

Risk and Volatility

Akari Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Innate Pharma has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.